Jnana Therapeutics to Participate in Upcoming Investor Conferences
27 févr. 2024 08h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...
Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU
30 janv. 2024 08h15 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics announces positive, statistically significant interim results from its ongoing clinical study of JNT-517 in individuals with PKU.
Jnana Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 janv. 2024 08h00 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics CEO Joanne Kotz, PhD, will present at the J.P. Morgan Healthcare Conference on Monday, January 8, at 5:30pm PT.
Jnana Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Virtual Conference
06 déc. 2023 08h00 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics CEO Joanne Kotz will participate in a fireside chat on Dec. 13 at the RBC Capital Markets Healthcare Private Company Conference.
Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 08h00 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics CEO Joanne Kotz, Ph.D., will present a corporate overview at the Piper Sandler 35th Annual Healthcare Conference.
Jnana Therapeutics to Participate in Upcoming Investor Conferences
05 oct. 2023 08h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics to Participate in Upcoming Investor Conferences
06 sept. 2023 08h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets,...
Jnana Therapeutics Presents Additional Data from Phase 1a Clinical Study of JNT-517 at SSIEM Annual Symposium
31 août 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 demonstrated sustained, dose-dependent pharmacodynamic effects and was safe and well tolerated in healthy volunteers Phase 1b study is ongoing in individuals with PKU BOSTON, Aug. 31, 2023 ...
Jnana Therapeutics Announces Dosing of First Participant in Phase 1b Clinical Trial of JNT-517 in Individuals with PKU
09 août 2023 07h00 HE
|
Jnana Therapeutics, Inc.
JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals Upcoming Oral Presentation of Phase 1a Study...
Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D
19 juil. 2023 07h00 HE
|
Jnana Therapeutics, Inc.
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for...